Drug intelligence / Profile preview

BCWP-D018

Development stage: Preclinical
Lead developer: BC World Pharm
Modality: Small Molecules
Administration: Subcutaneous

Overview

BCWP-D018 is a preclinical-stage small molecule candidate developed by BCWorld Pharma for the treatment of obesity. The drug is designed as a long-acting injectable (LAI) formulation, aiming to provide a sustained therapeutic effect over a one-month duration. This approach is intended to improve patient adherence and convenience compared to daily oral or more frequent injectable treatments. The program is currently in the formulation research stage, leveraging BCWorld Pharma's expertise in microsphere and sustained-release drug delivery systems to optimize the pharmacokinetic profile for weight management.

Beyond the preview

Go deeper on BCWP-D018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCWP-D018.

Explore the full profile